Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study

Approximately 7 ‒9% of adults in Denmark and Sweden have diabetes [1], with type 2 diabetes (T2D) accounting for 85–91% of cases [2,3]. T2D is a substantial healthcare challenge, profoundly impacting affected individuals and placing a heavy burden on society [4,5]. Diabetes and primary care guidelines recommend a patient-centred approach to T2D treatment, considering factors including patient preference, impact on body weight (BW), cardiovascular and hypoglycaemia risk, and drug efficacy [6,7].
Source: Primary Care Diabetes - Category: Primary Care Authors: Tags: Original research Source Type: research